The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. by Wiessner, C, Wiederhold, K, Tissot, A, Frey, P, Danner, S, Jacobson, L, Jennings, G, Lüönd, R, Ortmann, R, Reichwald, J, Zurini, M, Mir, A, Bachmann, M, Staufenbiel, M